FamiCord AG (ETR:V3V)

Germany flag Germany · Delayed Price · Currency is EUR
5.60
-0.05 (-0.88%)
At close: Jan 23, 2026
35.27%
Market Cap97.62M
Revenue (ttm)88.29M
Net Income (ttm)-9.80M
Shares Out17.43M
EPS (ttm)-0.58
PE Ration/a
Forward PE70.00
Dividendn/a
Ex-Dividend Daten/a
Volume1,805
Average Volume2,425
Open5.70
Previous Close5.65
Day's Range5.50 - 5.70
52-Week Range3.70 - 7.65
Beta0.78
RSI40.09
Earnings DateApr 30, 2026

About FamiCord AG

FamiCord AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the compa... [Read more]

Sector Healthcare
Founded 1997
Employees 771
Stock Exchange Deutsche Börse Xetra
Ticker Symbol V3V
Full Company Profile

Financial Performance

In 2024, FamiCord AG's revenue was 82.18 million, an increase of 6.65% compared to the previous year's 77.06 million. Losses were -12.14 million, 550.7% more than in 2023.

Financial Statements

News

FamiCord AG Surpasses 2024 Earnings with Vita 34 Boost, Early Figures Show

FamiCord AG, Europe's top cell bank, surpassed its 2024 earnings forecast, with revenue hitting EUR 82.2 million and EBITDA at EUR 8.8 million, outpacing expectations by nearly 10%. Jetzt den vollstän...

10 months ago - Wallstreet:Online

Vita 34 Boosts Revenue, Profitability & Cash Flow in Q3 2024

Vita 34 AG, Europe's top cell bank, reports robust growth with a 6.3% revenue increase and a remarkable 77.5% rise in EBITDA, driven by strategic expansions and high demand for placenta tissue banking...

1 year ago - Wallstreet:Online

EQS-News: Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024

EQS-News: Vita 34 AG / Key word(s): 9 Month figures Vita 34 continues to show increasing revenue, improved profitability and stronger cash generation in the third quarter of 2024 22.11.2024 / 07:00 CE...

1 year ago - Wallstreet:Online

Vita 34 Boosts Operating Cash Flow in H1 2024, Continues Positive Trend

Vita 34 AG has reported robust financial growth in the first half of 2024, with revenues up by 4.9% and EBITDA soaring by 76.4%. The company remains optimistic about its full-year outlook, anticipatin...

1 year ago - Wallstreet:Online

EQS-News: Vita 34 continues positive trend in the first half of 2024 and once again significantly increases operating cash flow

EQS-News: Vita 34 AG / Key word(s): Half Year Results/Half Year Report Vita 34 continues positive trend in the first half of 2024 and once again significantly increases operating cash flow 30.08.2024 ...

1 year ago - Wallstreet:Online

EQS-Adhoc: Subsidiaries of Vita 34 reach agreement with US licensor

EQS-Ad-hoc: Vita 34 AG / Key word(s): Agreement/Scheme of Arrangement Subsidiaries of Vita 34 reach agreement with US licensor 09-Aug-2024 / 17:04 CET/CEST Disclosure of an inside information acc. to ...

1 year ago - Wallstreet:Online